Bright Minds Biosciences opened lower at $23.33, compared with its previous close of $23.45. In the last trading session, the stock traded between $22.09 and $23.99. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Bright Minds Biosciences is now worth
$ 67.67
Resulting in a loss of
$ 32.33 (32.33%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.58 (-2.47%)
Day High
$23.99
Day Low
$22.09
Day Open
$23.33
Prev Close
$23.45
Volume
1,06,121
1W Return
21.46%
1M Return
-57.74%
3M Return
-71.47%
6M Return
-73.57%
1Y Return
-61.39%
Market Cap ($ Mn)
226
PE Ratio
-
PB Ratio
3.29
PEG Ratio
-
ROE
-24.21%
ROCE
-27.14%
EPS (TTM)
$-0.24
1 Week
21.46%
1 Month
-57.74%
3 Months
-71.47%
6 Months
-73.57%
9 Months
-70.65%
Kirby McInerney probes Bright Minds over FDA trial halt and share drop
Kirby McInerney LLP investigates Bright Minds for potential securities law violations. Shares fell 52.3% after FDA placed Phase 2 BMB-101 trial on partial clinical hold. FDA cited mouse toxicity and insufficient pharmacokinetic data as reasons for halt. Levi & Korsinsky LLP is also investigating the company for misleading statements.
YesterdayBTIG maintains Buy on Bright Minds Biosciences, cuts target to $37
BTIG analyst Thomas Shrader maintains a Buy rating on Bright Minds Biosciences. Price target lowered from $147 to $37. Rating status remains unchanged despite significant target reduction.
9 days agoFDA places partial clinical hold on Bright Minds' BMB-101 trial
FDA placed a partial clinical hold on Bright Minds' Phase 2 BMB-101 trial for DEEs. Hold relates to mouse toxicity and inadequate pediatric safety data. Company asserts mouse toxicity was incidental and not seen in other species. Full Partial Clinical Hold Letter expected from FDA within 30 days.
10 days agoBright Minds to join FPWR symposium; rescinds 44,500 stock options
Bright Minds Biosciences will attend the FPWR Research Symposium and PWS Family Conference in Philadelphia from October 7 to October 10, 2026. The company rescinded an officer's stock option exercise involving 44,500 common shares, returning them to treasury and refunding the exercise price. BMB-101 is being evaluated in the NOVA Phase 2a study, with hyperphagia reduction as the primary endpoint. The Scientific Advisory Board was expanded in November 2025 with four global PWS experts.
1mo agoBright Minds Biosciences to present at Cantor and H.C. Wainwright conferences
Bright Minds Biosciences (NASDAQ: DRUG) will present at the Cantor Global Healthcare Conference on September 9, 2026, at 1:35 pm ET. The company will also present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 4:00 pm ET. Bright Minds develops highly selective 5-HT2 agonists for epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Bright Minds Biosciences is now worth
$ 67.67
Resulting in a loss of
$ 32.33 (32.33%)
Note: Past profits do not guarantee future returns.
